Xilio Therapeutics Overview
- Founded
-
2016

- Status
-
Public
- Employees
-
78

- Stock Symbol
-
XLO

- Share Price
-
$2.47
- (As of Wednesday Closing)
Xilio Therapeutics General Information
Description
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.
Contact Information
Website
www.xiliotx.com
Formerly Known As
Akrevia Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Stock Exchange
NAS
Primary Office
- 828 Winter Street
- Suite 300
- Waltham, MA 02451
- United States
+1 (617) 000-0000
Xilio Therapeutics Timeline
Xilio Therapeutics Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.47 | $2.42 | $2.04 - $27.95 | $66.5M | 27.5M | 116K | -$3.24 |
Xilio Therapeutics Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 16,688 | 583,293 | ||
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (78,697) | (74,301) | (54,154) | (17,071) |
Net Income | (80,486) | (75,800) | (55,219) | (17,311) |
Total Assets | 196,352 | 218,060 | 36,317 | 62,722 |
Total Debt | 20,402 | 20,536 | 21,217 | 18,631 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Xilio Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Xilio Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Xilio Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable cl
Drug Discovery
Waltham, MA
78
As of 2022
00000
0000
0000-00-00
00000000
00000
Xilio Therapeutics Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
00000000 000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
Xilio Therapeutics Executive Team (15)
Xilio Therapeutics Board Members (25)
Name | Representing | Role | Since |
---|---|---|---|
Christina Rossi | Self | Board Member | 000 0000 |
Daniel Curran | Takeda Ventures | Board Member | 000 0000 |
Daniel Lynch | Self | Chairman of the Board | 000 0000 |
Michael Ross Ph.D | SV Health Investors | Board Member | 000 0000 |
Paul Clancy | Self | Chairman & Board Member | 000 0000 |
Xilio Therapeutics Signals
Xilio Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|